anticoagulants; Heparin-induced thrombocytopenia; perioperative care; thrombosis; vascular surgical procedures; Anesthesiology and Pain Medicine
Abstract :
[en] Background: Heparin-induced thrombocytopenia (HIT) is a severe immune-mediated complication of heparin therapy, potentially leading to life-threatening thrombotic events, referred to as HIT with thrombosis (HITT). Case Presentation: We report the case of a 46-year-old female patient with severe peripheral arterial occlusive disease who developed acute HITT after undergoing a covered endovascular reconstruction of the aortic bifurcation (CERAB). Perioperative heparin was administered during CERAB procedure. Low-molecular-weight heparin (LMWH), initially prescribed postoperatively, was replaced by apixaban due to thrombocytopenia. Despite this, an intra-stent thrombosis occurred, requiring urgent surgical revascularization. Intervention and Outcome: HITT was confirmed by a positive anti-PF4/heparin antibody assay and validated by functional platelet activation tests. Surgery was performed under danaparoid anticoagulation. Thrombectomy was achieved using a Fogarty catheter. The patient’s limb was reperfused, her platelet count normalized, and no hemorrhagic complications occurred. Postoperative management included a tailored anticoagulation regimen. Conclusion: Anticoagulation is the cornerstone of HITT. Vascular surgery in this pathology is particularly challenging due to the need for perioperative anticoagulation while avoiding heparin exposure. This case illustrates the importance of early recognition and personalized perioperative management in HITT. A multidisciplinary approach is essential to ensure optimal outcomes while mitigating both thrombotic and hemorrhagic risks.
Disciplines :
Anesthesia & intensive care
Author, co-author :
REYNKENS, Anaïs ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'anesthésie - réanimation
Peters, Pierre ; Université de Liège - ULiège > Département des sciences cliniques
Stiennon, Laurie ; Centre Hospitalier Universitaire de Liège - CHU > > Service de chirurgie cardio-vasculaire et thoracique
Hans, Grégory ; Université de Liège - ULiège > Département des sciences cliniques > Anesthésie et réanimation
Schyns, Olivier ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'anesthésie - réanimation
Bonhomme, Vincent ; Université de Liège - ULiège > Département des sciences cliniques > Anesthésie et réanimation
Lecoq, Jean-Pierre ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'anesthésie - réanimation
Language :
English
Title :
Management of a thrombotic event in an acute heparin induced thrombocytopenia with thrombosis (HITT) patient: case report and narrative
Pishko AM. and Cuker A. 2021. Heparin-induced t hrombocyt openi a and cardi ovascul ar surgery. Hemat ol ogy Am Soc Hemat ol Educ Program. 2021;2021(1):536-544.
Camoin-Jau L., Mariotti A., Suchon P., and Morange PE. 2022. La thrombopénie induite par héparine: mise au point. Rev Med Interne. 2022;43(1):18-25.
Greinacher A. 2015. Clinical practice. Heparin-Induced Thrombocytopenia. N Engl J Med. 2015;373(3):252-261.
Morgan RL., Ashoorion V., Cuker A., Begum H., Ross S. and Martinez N. et al. 2020. Management of heparin-induced thrombocytopenia: systematic reviews and meta-analyses. Blood Adv. 2020;4(20):5184-5193.
Watson H., Davidson S., and Keeling D. 2012. Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: Second edition. Br J Haematol. 2012;159(5):528-540.
Nicolas D., Nicolas S., Hodgens A. and Reed M. 2023. Heparin-Induced Thrombocytopenia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
Warkentin TE. 2016. Clinical picture of heparin-induced thrombocytopenia (HIT) and its differentiation from non-HIT thrombocytopenia. Thromb Haemost. 2016;116(5):813-822.
Koster A., Nagler M., Erdoes G. and Levy JH. 2022. Heparin-induced Thrombocytopenia: Perioperative Di agnosi s and Management. Anest hesi ol ogy. 2022;136(2):336-344.
Linkins LA., Dans AL., Moores LK., Bona R., Davidson BL. and Schulman S. et al. 2012. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 SUPPL.):e495S-e530S.
Skeith L., Baumann Kreuziger L., Crowther MA. and Warkentin TE. A practical approach to evaluating postoperative thrombocytopenia. Blood Adv. 2020 Feb25;4(4):776-783.
Cuker A., Arepally GM., Chong BH., Cines DB., Greinacher A. and Gruel Y. et al. 2018. American Society of Hematology 2018 guidelines for management of venous t hr omboembol i sm: hepar i n-i nduced thrombocytopenia. Blood Adv. 2018 Nov 27;2(22):3360-3392.
Cuker A., Gimotty PA., Crowther MA. and Warkentin TE. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood. 2012 Nov 15;120(20):4160-4167
Warkentin TE. and Linkins LA. 2010. Non-necrotizing heparin-induced skin lesions and the 4T’s score. J Thromb Haemost. 2010;8(7):1483-1485.
Ananthasubramaniam K., Shurafa M. and Prasad A. Heparin-induced thrombocytopenia and thrombosis. Prog Cardiovasc Dis. 2000 Jan-Feb;42(4):247-260.
Arepally GM. and Padmanabhan A. 2021. Heparin-Induced Thrombocytopenia: A Focus on Thrombosis. Arterioscler Thromb Vasc Biol. 2021 Jan;41(1):141-152.
Warkentin TE. 2018. Heparin-induced thrombocytopenia-associated thrombosis: from arterial to venous to venous limb gangrene. J Thromb Haemost. 2018;16(11):2128-2132.
Warkentin TE. and Anderson JAM. 2016. How I treat patients with a history of heparin-induced thrombocytopenia. Blood. 2016;128(3):348–59.
Gruel Y., De Maistre E., Pouplard C., Mullier F., Susen S. and Roullet S. et al. 2020. Diagnosis and management of heparin-induced thrombocytopenia. Anaesth Crit Care Pain Med. 2020;39(2):291-310.
Koster A., Faraoni D. and Levy JH. 2018. Argatroban and Bivalirudin for Perioperative Anticoagulation in Cardiac Surgery. Anesthesiology. 2018;128(2):390-400.
Maier CL., Connors JM., Levy JH. 2024. Troubleshooting heparin resistance. Hematology Am Soc Hematol Educ Program. 2024;2024(1):186–191.
Seider S., Ross M., Pretorius V. and Maus T. 2019. The Use of Cangrelor and Heparin for Anticoagulation in a Patient Requiring Pulmonary Thromboendarterectomy Surgery with Suspected Heparin-Induced Thrombocytopenia. J Cardiothorac Vasc Anesth. 2019;33(4):1050-1053.
Gernhofer YK., Ross M., Khoche S. and Pretorius V. 2018. The use of cangrelor with heparin for left ventricular assist device implantation in a patient with acute heparin-induced thrombocytopenia. J Cardiothorac Surg. 2018;13(1).
Welsby IJ., Um J., Milano CA., Ortel TL., and Arepally G. 2010. Plasmapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia. Anesth Analg. 2010;110(1):30-35.
Linkins LA., Hu G., and Warkentin TE. 2018. Systematic review of fondaparinux for heparin-induced thrombocytopenia: When there are no randomized cont rol l ed t ri al s. Res Pract Thromb Haemost. 2018;2(4):678-683.
Adediran S. and Agostino N. 2017. Coexistence of Antiphospholipid Syndrome and Heparin-Induced Thrombocytopenia in a Patient with Recurrent Venous Thromboembolism. Case Rep Hematol. 2017;2017:3423548.
Tun NT., Krishnamurthy M. and Snyder R. 2015. Catastrophic antiphospholipid syndrome and heparin-induced thrombocytopenia-related diseases or chance association? Blood Coagul Fibrinolysis. 2015;26(2):214– 219.
